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Renal replacement therapyAbstract Background: Recommendations regarding vancomycin dosing and monitoring in criti-
cally ill patients on continuous renal replacement therapy (CRRT) are limited. This is a retrospec-
tive study to assess the adequacy of current vancomycin dosing and monitoring practice for patients
on CRRT in a tertiary hospital in Riyadh, Saudi Arabia.
Methods: A retrospective chart review of adult patients admitted between 1 April 2011 and 30
March 2013 to critical care and received intravenous vancomycin therapy whilst on CRRT was per-
formed.
Results: A total of 68 patients received intravenous vancomycin therapy whilst on CRRT, of
which 32 met the inclusion criteria. Fifty-one percent were males and median (range) age was
62.5 (19 – 90) years. Median APACHE II score was 33.5 (22–43) and median Charlson Comorbidity
Score was 4 (0–8). The mean (± standard deviation) dose of vancomycin was 879.9 mg
(± 281.2 mg) for an average duration of 5.9 days (± 3.7 days). All patients received continuous
veno-venous haemoﬁltration (CVVH). A total of 55 vancomycin level readings were available from
the study population, ranging from 6.6 to 41.3, with wide variations within the same sampling time
frames. Vancomycin levels of > 15 mg/L or were achieved at least once in 24 patients (75.0%), but
only 11 patients (34.3%) had 2 or more serum vancomycin level readings of 15 mg/L or more.
328 A.S. Omrani et al.Conclusion: Therapeutic vancomycin levels are difﬁcult to maintain in critically ill patients who
are receiving IV vancomycin therapy whilst on CRRT. Aggressive dosing schedules and frequent
monitoring are required to ensure adequate vancomycin therapy in this setting.
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intervals.1. Introduction
Vancomycin is an important antimicrobial agent for the treat-
ment of Gram-positive bacterial infections (Rybak, 2006). It
has been shown that for optimal clinical outcomes, the ratio
of area under the curve (AUC) of serum vancomycin concen-
tration to bacterial minimum inhibitory concentration (MIC)
should be maintained at 400 or above (Kullar et al., 2011;
Rybak et al., 2009). Such ratio is best predicted in clinical
practice by serum vancomycin trough levels of 15 – 20 mg/L
(Rybak et al., 2009). Vancomycin dosing recommendations
have therefore been designed to achieve these pharmacokinetic
targets for patients with different levels of renal function
(Rybak et al., 2009; Liu et al., 2011). However, optimal vanco-
mycin dosing regimens for critically ill patients on continuous
renal replacement therapy (CRRT) remain unclear (Petejova
et al., 2014; Chaijamorn et al., 2011).
Acute renal impairment is common in critically ill patients,
many of who require renal replacement therapy pending the
recovery of their kidney function (Uchino et al., 2005). CRRT
has the advantage of closely simulating physiological renal
clearance without the haemodynamic instability associated
with intermittent haemodialysis (IHD) (Dirkes and Hodge,
2007). CRRT however, results in considerable alterations in
the pharmacokinetics of various antimicrobial agents,
including vancomycin (Chaijamorn et al., 2011; Bouman
et al., 2006). Given the importance of early appropriate antimi-
crobial therapy for critically ill patients, effective vancomycin
dosing is essential (Dellinger et al., 2013). This study was
undertaken to assess the adequacy of current vancomycin dos-
ing and monitoring practice in critically ill patients requiring
CRRT in a large tertiary care centre in Riyadh, Saudi Arabia.
2. Materials and methods
We performed a retrospective chart review of all patients aged
18 years or more who were admitted to the intensive care unit
(ICU) in our institution during the period from 1 April 2011 to
31 March 2013 and received two doses or more of intravenous
vancomycin therapy whilst on CRRT. Interruptions totalling
6 h or less within any 24 h period of CRRT were permitted.
We excluded pregnant women and patients with extensive
burns. Details of vancomycin dosing regimens, renal replace-
ment variables and serum vancomycin levels were recorded.
Data were analysed using Microsoft Excel (Microsoft Inc.,
Redmond, USA).
3. Results
During the study period, a total of 68 patients received intra-
venous vancomycin therapy whilst on CRRT. Twenty-seven
patients received less than 2 doses of intravenous vancomycin
whilst on CRRT, 8 had incomplete CRRT data and 1 patientwas aged less than 18 years. Thirty-two patients were included
in the analysis, of which 18 (51.4%) were males. Median
(range) patient age was 62.5 (19 – 91) years with median
APACHE II score of 33.5 (22–43) and median Charlson
Comorbidity Score of 4 (0–8). The mean (± standard devia-
tion) length of stay in ICU was 28.4 (± 21.2) days. Mean body
weight was 65.4 (± 12.8) kg. Patients received an average
intravenous vancomycin dose of 879.9 mg (± 281.2 mg) for a
mean duration of 5.9 days (± 3.7 days). The median number
of doses of intravenous vancomycin received per patient was
4 (2–38). Mean serum creatinine at the time of starting CRRT
was 271.8 lmole/L (± 179.4 lmole/L) with an average esti-
mated creatinine clearance of 271.8 mL/min (± 179.4 mL/
min). Mean serum albumin was 27.8 (± 13.9) g/L. CRRT
mode in all patients was continuous veno-venous haemoﬁltra-
tion (CVVH).
A total of 55 vancomycin level readings were available from
the study population. Overall, vancomycin serum levels ranged
from 6.6 to 41.3 mg/L, with wide variations within the same
sampling time frames (Fig. 1). Target vancomycin level of
15 mg/L or higher was achieved at least once in 24 patients
(75.0%). However, only 11 patients (34.3%) had 2 or more
serum vancomycin level readings of 15 mg/L or more.
4. Discussion
Our results demonstrate wide variation in serum vancomycin
levels in critically ill patients on CRRT. Furthermore, vanco-
mycin serum levels did not reach therapeutic levels in at least
25% of patients. Of more concern is the fact that only one
third of patients (34.3%) can be shown to have maintained
adequate vancomycin levels over at least two assessments.
Similar results were reported previously. For example, in a
retrospective cohort study, Wilson et al. reported that 44% of
medical ICU and 49% of surgical ICU vancomycin levels
obtained from patients on CRRT were below the target of
Vancomycin in CRRT 32915 mg/L (Wilson and Berns, 2012). Likewise, Petejova et al. found
that in 10 out of 17 patients who received vancomycin whilst on
CRRT, vancomycin serum levels dropped below 10 mg/L within
the ﬁrst 6 h of the infusion (Petejova et al., 2014). In a more recent
study, only 1 out of 4 patients receiving intravenous vancomycin
whilst on CRRT had any detectable serum vancomycin levels
24 h after the infusion (Paciullo et al., 2013).
It has become recently evident that vancomycin is removed
very efﬁciently during CRRT. In a prospective pharmacoki-
netic study of 7 critically ill patients on CVVH, the mean siev-
ing coefﬁcient of vancomycin was 0.71 (± 0.13). Clearance of
vancomycin by CVVH constituted 59.4 (± 20.8) of total van-
comycin clearance (Chaijamorn et al., 2011). Continuous
veno-venous haemodiaﬁltration (CVVHD) results in even
more efﬁcient vancomycin clearance, with a sieving coefﬁcient
of 0.7 (± 0.1) and total clearance reaching up to 76%
(± 16.5%) of total vancomycin clearance (DelDot et al.,
2004). In addition to the mode of CRRT, vancomycin clear-
ance is signiﬁcantly higher and thus therapeutic levels are more
difﬁcult to achieve in patients on higher rates of haemoﬁltra-
tion (Petejova et al., 2014; Frazee et al., 2012).
There have been a number of attempts to recommend dos-
ing algorithms that ensure adequate vancomycin therapy dur-
ing CRRT (Chaijamorn et al., 2011; Wilson and Berns, 2012;
Heintz et al., 2009; Kuang et al., 2007). Those recommenda-
tions however, are based largely on limited data derived from
small studies, simulation models or IHD studies. Given the
apparent unpredictability of vancomycin serum levels in criti-
cally ill patients receiving CRRT, the variability of various fac-
tors that inﬂuence its clearance and the potentially rapidly
changing clinical parameters in such patients, several authors
recommend aggressive vancomycin dosing and monitoring
regimens to ensure adequate and consistent therapy
(Petejova et al., 2014; Chaijamorn et al., 2011; Wilson and
Berns, 2012; Paciullo etal., 2013; Frazee et al., 2012).
5. Conclusion
Vancomycin serum levels are frequently insufﬁcient in criti-
cally ill patients receiving CRRT. One possible strategy to
optimize vancomycin therapy in this setting is to aim for
12 hourly dosing with serum level monitoring as early as
6–12 h after the ﬁrst infusion followed by dynamic adjustment
of dose and/or dosing intervals to maintain serum levels within
therapeutic targets.
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